Marker Therapeutics jumps after blood cancer trial data

Marker Therapeutics

26/08/2025 12:46

** Shares of drug developer Marker Therapeutics MRKR.O up 29% at $1.63 premarket

** Co reports data from its ongoing early-stage trial testing its experimental therapy, MT-601, in patients with relapsed B-cell lymphoma, a type of blood cancer that has returned after previous treatment

** Co says 66% of patients saw their cancer shrink or disappear, with 50% showing no detectable cancer after treatment

** The therapy had no severe side effects, co says

** As of last close, stock down 60% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))